All In Biotech

Drug Trial Radar · NCT05513950

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).

A Phase Ib, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Intravenous Monoclonal Antibody (mAb) After Single Ascending Doses in Subjects Affected by Idiopathic Pulmonary Fibrosis.

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Jan 25, 2023

Primary completion

Jun 17, 2024

Study completion Jun 17, 2024

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Aug 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it. The body's immune response to the study drug was evaluated. Chiesi conducted this study in patients affected by idiopathic pulmonary fibrosis (IPF, a progressive and chronic lung disease). Chiesi performed this study to establish the drug doses that would be suitable for future studies (a dose finding study).

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • CHF10067 starting dose -- 1000mg (Cohort A)Biological

    Intravenous administration of a starting dose of the monoclonal antibody

  • CHF10067 intermediate dose -- 2000mg (Cohort B)Biological

    Intravenous administration of an intermediate dose of the monoclonal antibody

  • CHF10067 high dose -- 3000mg (Cohort C)Biological

    Intravenous administration of a high dose of the monoclonal antibody

  • PlaceboDrug

    Intravenous administration of a physiological solution as placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1_Subjects With Adverse Event (AE); Non-Serious AEs and Serious AEsTime frame: From pre-dose (baseline) up to day 84.

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • PHI University Clinic of Pulmonology and Allergology

    Skopje, North Macedonia

  • Medical Center of Limited Liability Company "Arensia Exploratory Medicine", department of Clinical Trials

    Kyiv, Ukraine

  • Queen Elizabeth Hospital - NIHR Birmingham Clinical Research Facility - University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • Royal Papworth Hospital NHSFT - Cambridge Biomedical Campus

    Cambridge, United Kingdom

  • University of Dundee, NHS Tayside - Ninewells Hospital & Medical School

    Dundee, United Kingdom

  • Interstitial Lung Disease Research - NHS Lothian - Royal Infirmary of Edinburgh,

    Edinburgh, United Kingdom

  • Liverpool Clinical Research Facility - Liverpool University Hospital Foundation Trust

    Liverpool, United Kingdom

  • Medicines Evaluation Unit - The Langley Building

    Manchester, United Kingdom

  • University Hospital Southampton - Department of Respiratory Medicine

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.